Carlo Russo
Chief Tech/Sci/R&D Officer bei GENENTA SCIENCE S.P.A.
Vermögen: 2 Mio $ am 31.03.2024
Profil
Carlo Russo is currently the Chief Medical Officer & Head-Development at Genenta Science SpA since 2021.
Prior to this, he was the President & CEO at VaxInnate Corp.
He also served as the Chief Medical Officer & Executive Vice President at Adverum Biotechnologies, Inc. in 2016.
Dr. Russo holds a doctorate degree from the University of Genoa.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
GENENTA SCIENCE SPA
3,28% | 19.04.2023 | 598 417 ( 3,28% ) | 2 Mio $ | 31.03.2024 |
Aktive Positionen von Carlo Russo
| Unternehmen | Position | Beginn |
|---|---|---|
| GENENTA SCIENCE S.P.A. | Chief Tech/Sci/R&D Officer | 01.01.2021 |
Ehemalige bekannte Positionen von Carlo Russo
| Unternehmen | Position | Ende |
|---|---|---|
| ADVERUM BIOTECHNOLOGIES, INC. | Chief Tech/Sci/R&D Officer | 01.07.2016 |
VaxInnate Corp.
 VaxInnate Corp. Pharmaceuticals: MajorHealth Technology VaxInnate Corp. develops novel, proprietary vaccines for infectious diseases. It engages in the development and production of vaccines for pandemic and seasonal influenza diseases. The firm's products include Flagellin.HuHA and flagellin.AvHA, which are fusion proteins linking a potent immune stimulator, the bacterial protein flagellin, with immunoprotective domain of viral hemagglutinin. The company was founded by Ruslan Medzhitov, Michael I. Sherman and Richard Flavell in 2002 and is headquartered in Cranbury, NJ. | Chief Executive Officer | - |
Ausbildung von Carlo Russo
| University of Genoa | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| ADVERUM BIOTECHNOLOGIES, INC. | Health Technology |
| GENENTA SCIENCE S.P.A. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
VaxInnate Corp.
VaxInnate Corp. Pharmaceuticals: MajorHealth Technology VaxInnate Corp. develops novel, proprietary vaccines for infectious diseases. It engages in the development and production of vaccines for pandemic and seasonal influenza diseases. The firm's products include Flagellin.HuHA and flagellin.AvHA, which are fusion proteins linking a potent immune stimulator, the bacterial protein flagellin, with immunoprotective domain of viral hemagglutinin. The company was founded by Ruslan Medzhitov, Michael I. Sherman and Richard Flavell in 2002 and is headquartered in Cranbury, NJ. | Health Technology |
